Targeted nasal vaccination provides antibody-independent protection against staphylococcus aureus

Journal of Infectious Diseases

Volumn 209, Issue 9, 2014, Pages 1479-1484

  Misstear, Karen ^a   Mcneela, Edel A ^a   Murphy, Alison G ^a   Geoghegan, Joan A ^a   O'keeffe, Kate M ^a   Fox, John ^b   Chan, Kin ^b   Heuking, Simon ^c   Collin, Nicolas ^c   Foster, Timothy J ^a   Mcloughlin, Rachel M ^a   Lavelle, Ed C ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b Citywest Business Park   (Ireland)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

adjuvant; cellular immunity; mucosal; nanoparticle; Staphylococcus aureus; vaccine

Indexed keywords

ADJUVANT; CELLULAR IMMUNITY; MUCOSAL; NANOPARTICLE; STAPHYLOCOCCUS AUREUS; VACCINE;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, NEUTRALIZING; BACTERIAL LOAD; FEMALE; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NANOPARTICLES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL VACCINES; STAPHYLOCOCCUS AUREUS;

EID: 84898651245     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jit636     Document Type: Article

References (15)

1. McKenna M. Vaccine development: Man vs MRSA. Nature 2012; 482:23-5
2. Bagnoli F, Bertholet S, Grandi G. Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trials. Front Cell Infect Microbiol 2012; 2:16
3. Spellberg B, Daum R. Development of a vaccine against Staphylococcus aureus. Semin Immunopathol 2012; 34:335-48
4. Lin L, Ibrahim AS, Xu X, et al. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog 2009; 5:e1000703
5. Yamamoto M, Pascual DW, Kiyono H. M cell-Targeted mucosal vaccine strategies. Curr Top Microbiol Immunol 2012; 354:39-52
6. Clark MA, Blair H, Liang L, Brey RN, Brayden D, Hirst BH. Targeting polymerised liposome vaccine carriers to intestinal M cells. Vaccine 2001; 20:208-17
7. Foster N, Clark MA, Jepson MA, Hirst BH. Ulex europaeus 1 lectin targets microspheres to mouse Peyer's patch M-cells in vivo. Vaccine 1998; 16:536-41
8. Lambkin I, Pinilla C, Hamashin C, et al. Toward targeted oral vaccine delivery systems: Selection of lectin mimetics from combinatorial libraries. Pharm Res 2003; 20:1258-66
9. McNeela EA, Burke A, Neill DR, et al. Pneumolysin activates the NLRP3 inflammasome and promotes proinflammatory cytokines independently of TLR4. PLoS Pathog 2010; 6:e1001191
10. McLoughlin RM, Lee JC, Kasper DL, Tzianabos AO. IFN-gamma regulated chemokine production determines the outcome of Staphylococcus aureus infection. J Immunol 2008; 181:1323-32
11. Sun HX, Xie Y, Ye YP. Advances in saponin-based adjuvants. Vaccine 2009; 27:1787-96
12. Manocha M, Pal PC, Chitralekha KT, et al. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex europaeus-I lectin as M cell target. Vaccine 2005; 23:5599-617
13. Josefsson E, Hartford O, O'Brien L, Patti JM, Foster T. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J Infect Dis 2001; 184:1572-80
14. Narita K, Hu DL, Mori F, Wakabayashi K, Iwakura Y, Nakane A. Role of interleukin-17A in cell-mediated protection against Staphylococcus aureus infection in mice immunized with the fibrinogen-binding domain of clumping factor A. Infect Immun 2010; 78:4234-42
15. Spellberg B, Ibrahim AS, Yeaman MR, et al. The antifungal vaccine derived from the recombinant N terminus of Als3p protects mice against the bacterium Staphylococcus aureus. Infect Immun 2008; 76:4574-80.